Table 2

Change in key outcome measures from baseline to day 28 in a randomized, double-blind, placebo-controlled trial of NGM282 in patients with type 2 diabetes

Difference in least squares means (95% CI) (NGM282 vs. placebo)
Key outcome measureNGM282 2 mg
(n = 21)P valueNGM282 5 mg
(n = 19)P valueNGM282 10 mg
(n = 20)P value
Glucose (mg/dL)0 (−12.6, 12.6)1.00−7.2 (−19.8, 9.0)0.94−7.2 (−19.8, 9.0)0.94
HbA1c (%)0.25 (0, 0.5)0.190.3 (0, 0.5)0.190 (−0.3, 0.4)0.76
HbA1c (mmol/mol)2.7 (0, 5.5)0.193.3 (0, 5.5)0.190 (−3.3, 4.4)0.76
Fructosamine (μmol/L)2.6 (−14.3, 19.4)0.97−1.7 (−19.3, 15.9)0.99−17.7 (−35.0, −0.5)0.043
GTT glucose AUC0.8 (−1.1, 2.6)0.661.0 (−1.0, 3.1)0.460.5 (−1.5, 2.5)0.89
GTT insulin AUC−6.0 (−12.2, 0.8)0.22−8.3 (−16.7, −2.8)0.06−7.4 (−21.0, 0.8)0.22
Insulin (μIU/mL)−1.5 (−6.7, 3.6)0.80−1.0 (−6.9, 4.8)0.95−3.7 (−9.5, 2.0)0.28
HOMA-IR0.9 (−1.3, 3.1)0.600.9 (−1.5, 3.4)0.66−0.9 (−3.2, 1.4)0.64
HOMA-bcf−4.5 (−16.0, 11.0)1.00−1.5 (−19.0, 17.0)1.00−13.5 (−27.0, 6.0)0.30
Weight (kg)−0.6 (−1.9, 0.6)0.50−0.7 (−2.0, 0.6)0.46−1.5 (−2.8, −0.2)0.019
  • SAS 9.4 was used for all analyses. The difference between NGM282 and placebo groups was analyzed using ANCOVA, with treatment group as a factor and baseline values of the outcome as covariates. All statistical analyses were carried out using two-sided tests at the 5% level of significance. AUC, area under curve.